我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

瑞舒伐他汀对冠状动脉慢血流患者冠状动脉贮备功能和超敏C反应蛋白的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2012年第1期
页码:
71-74
栏目:
临床研究
出版日期:
2012-02-25

文章信息/Info

Title:
Effects of rosuvastatin on coronary flow reserve and high-sensitivity C-reactive protein in patients with slow coronary flow
作者:
邹 祎; 肖秀金; 余泽洪; 陈小林; 汤立军; 冼伟进; 王晓霞
(江门市人民医院心内科，广东 江门 529000)
Author(s):
ZOU Yi;  XIAO Xiu-jin;  YU Ze-hong;  CHEN Xiao-lin;  TANG Li-jun;  XIAN Wei-jin;  WANG Xiao-xia
(Department of Cardiology, Jiangmen People’s Hospital, Jiangmen 529051, Guangdong, China)
关键词:
冠状动脉慢血流; 瑞舒伐他汀; 血流贮备功能; 超敏C反应蛋白
Keywords:
slow coronary flow;  rosuvastatin;  coronary flow reserve;  high-sensitivity C-reactive protein
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的:探讨长期瑞舒伐他汀治疗对冠状动脉慢血流患者冠脉贮备功能（CFR）和超敏C反应蛋白（hsCRP）的影响。方法： 选择冠状动脉造影正常但存在冠脉慢血流的患者48例，所有患者随机分为试药组和对照组，对照组(22例)予常规治疗，试药组(26例)在常规治疗基础上加用瑞舒伐他汀20 mg/d，治疗期为6个月。治疗前后测定两组患者的血脂，hsCRP，利用腺苷负荷超声记录左前降支远端血流频谱评评价CFR。结果： 经过6个月瑞舒伐他汀的治疗后，试药组总胆固醇（TC）和低密度脂蛋白胆固醇（LDL-C）较对照组明显下降，［TC：(3.2±0.9)mmol/L vs. (5.4±1.2)mmol/L,P<0.05;LDL-C：(2.1±0.7)mmol/L vs. (3.4±0.8)mmol/L，P<0.05］。hsCRP较对照组明显下降 ［(2.1±1.4)mg/L vs. (3.7±2.1)mg/L，P<0.05］。试药组静息冠脉血流速度（bCFV）较对照组和治疗前显著下降 ［(21±6)cm/s vs. (26±5)cm/s和(21±6)cm/s vs. (25±7)cm/s,P<0.05］，而最大冠状动脉扩张状态hCFV较对照组和治疗前增加［(71±9)cm/s vs. (56±8)cm/s和(71±9)cm/s vs.(56±10)cm/s,P<0.05］，冠状动脉血流储备CFR较对照组和治疗前明显增加［(3.2±0.6)cm/s vs. (2.1±0.5)cm/s和(3.2±0.6)cm/s vs.(2.2±0.4)cm/s,P<0.05)］。结论： 冠状动脉慢血流患者经过瑞舒伐他汀治疗可以有效改善冠脉贮备功能。
Abstract:
AIM:To investigate the effect of rosuvastatin on coronary flow reserve (CFR) and high-sensitivity C-reactive protein (hsCRP) in patients with slow coronary flow. METHODS: A total of 48 patients with slow coronary flow but normal coronary angiography were included in this study. Patients were divided into rosuvastatin group (20 mg/day for 6 months, n=26) and control group (non-statin, n=22) and blood cholesterol and hsCRP were measured. Doppler coronary flow velocity and Doppler reserve measurement of distal left anterior descending artery were recorded at rest and adenosine infusion-induced hyperemia state. CFR was calculated by the ratio of maximal hyperemia and baseline peak diastolic coronary flow velocity (hCFV and bCFV) before and after rosuvastatin treatment. RESULTS: After treatment for 6 months, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in rosuvastatin group were significantly lower than those in control group ［TC: (3.2±0.9) mmol/L vs. (5.4±1.2) mmol/L, P<0.05; LDL-C: (2.1±0.7) mmol/L vs. (3.4±0.8) mmol/L, P<0.05］. hsCRP in rosuvastatin group was significantly lower than in control group ［(2.1±1.4) mg/L vs. (3.7±2.1) mg/L, P<0.05］. Compared with those in control group and rosuvastatin group before treatment, treatment for 6 months with rosuvastatin reduced bCFV ［(21±6)cm/sec vs. (26±5)cm/sec and (21±6)cm/sec vs. (25±7)cm/sec, P<0.05］, increased hCFV ［(71±9) cm/sec vs. (56±8) cm/sec and (71±9) cm/sec vs. (56±10) cm/sec, P<0.05］, and increased CFR ［(3.2±0.6) cm/sec vs. (2.1±0.5) cm/sec and (3.2±0.6) cm/sec vs.(2.2±0.4) cm/sec, P<0.05］. CONCLUSION: Rosuvastatin may effectively improve coronary flow reserve and reduce hsCRP in patients with slow coronary flow.

参考文献/References

[1]Mangieri E,Macchiarelli G,Ciavolella M,et al.Slow coronary flow:clinical and histopathological features in patients with othwise normal epicardial coronary arteries[J].Cathet Cardiovasc Diagn,1996,37(2):375-381.

[2]Beltrame JF,Tumer SP,Leslie SL,et al.The angiographic and clinical benefits of mibefradil in the coronary slow phenomenon[J].J Am Coll Cardiol,2004,44(1):57-62.

[3]Erdogan D,Caliskan M,Gullu H,et al.Coronary flow reserve is impaired in patients with slow coronary flow[J].Atherosclerosis,2007,191(1):168-174.

[4]Beltrame JF,Limaye SB,Wuttke RD,et al.Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon[J].Am Heart J,2003,146(1):84-90.

[5]Camsari A,Ozcan T,Ozer C,et al.Carotid artery intima-media thickness correlates with intravascular ultrasound parameters in patients with slow coronary flow[J].Atherosclerosis,2008,200(2):310-314.

[6]Kosar F,Ermis N,Yologlu S,et al.Vascular endothelial function in patients with slow coronary flow[J].Coron Artery Dis,2003,14(2):155-161.

[7]Caliskan M,Erdogan D,Gullu H,et al.Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow[J].Clin Cardiol,2007,30(9):475-479.

[8]樊 瑛，杨树森，于江波,等.阿托伐他汀对冠状动脉血流缓患者冠状动脉血流储备的影响[J].中华心血管病杂志,2010,38(2):143-146.

[9]Cakmak M,Tanriverdi H,Cakmak N,et al.Simvastatin may improve myocardial perfusion abnormality in slow coronary flow[J].Cardiology,2008,110(1):39-44.

[10]刘艳红,张 梅,刘玲梅,等.短期应用辛伐他汀对大鼠缺血再灌注后心肌无复流的影响和潜在机制[J]. 中华心血管病杂志，2008,36(8):729-734.

[11]Ling MC,Ruddy TD,deKemp RA,et al.Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease[J].Am Heart J,2005,149(6):1137.

[12]Barutcu I,Sezgin AT,Sezgin N,et al.Increased high sensitive CRP level and its significance in pathogenesis of slow coronary flow[J].Angiology, 2007,58(4):401-407.

[13]Li JJ,Wu YJ,Qin XW,et al.Should slow coronary flow be considered as a coronary syndrome?[J].Med Hypotheses,2006,66(5):953-956.

备注/Memo

备注/Memo:
收稿日期：2011-04-27.作者简介:邹祎,副主任医师,硕士 Email:zy9272003@yahoo.com.cn
更新日期/Last Update: 2012-02-14